March 15th 2023
Factors including age, gender, and facility type may influence the likelihood of pain specialist referrals for lung cancer, suggesting a need for multidisciplinary pain management in this patient population.
March 14th 2023
February 22nd 2023
February 13th 2023
Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Trekking Through the Latest Updates for ROS1-Targeted Therapies
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC
Navigating the Latest Data on NTRK-Targeted Therapies
Community Practice Connections™: 17th Annual New York Lung Cancers Symposium
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
Show Me Your Care Plan™: Monitoring and Managing Patients With EGFR Exon20 Insertion+ NSCLC
Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care
Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers
Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care
Advancing Precision Care Through Biomarker-Driven Therapy: CEACAM5 as a Therapeutic Target in NSCLC
Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer
Medical Crossfire: How Should We Leverage Multidisciplinary Lung Cancer Care Teams in Managing Earlier Forms of NSCLC... When the Goal Is Cure?
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
Catching Them Early: A Real-World Case Discussion on the Application of Testing Methodologies to Identify Key Markers Across NSCLC
Expert Illustrations & Commentaries™: Exploring the Clinical Rationale for Antagonizing Inflammatory IL-1-beta Signaling in NSCLC
Onco-Nurse Academy™: Exploring an Advent of Targeted Therapies Across Advanced NSCLC Care and Strategies for Managing Adverse Events Associated With Treatment
Patient, Provider, and Caregiver Connection™: Shedding a Light on the Patient Journey with KRAS Mutated Lung Cancer
Clinical Vignettes®: Multidisciplinary Discussions on the Application of Novel EGFR Exon 20 Targeted Regimens for NSCLC Management
Expert Illustrations & Commentaries™: Exploring the Role of Novel Antibody-Drug Conjugates in Advanced NSCLC
Advances In™ NSCLC: Exploring CEACAM5 As A New Therapeutic Target
Community Practice Connections™: Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!
Community Practice Connections™: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care
Advances In™: The Role of NRG1 Fusions Across Tumor Types
Medical Crossfire®: Leveraging EGFR Mutation Profiles to Personalize Therapeutic Decisions in Resected and Metastatic NSCLC Settings
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!
Antonio Calles, MD, Highlights Promising Preliminary Activity of Lurbinectedin and Pembrolizumab in Relapsed SCLCNovember 25th 2022
Early results from the phase 1/2 LUPER study indicated that lurbinectedin in combination with pembrolizumab demonstrated no unexpected toxicities and promising preliminary efficacy in the second line for patients with relapsed small cell lung cancer, according to Antonio Calles, MD.
Sinoatrial Node Radiation During CRT May Increase Risk of Atrial Fibrillation in SCLC and NSCLCNovember 1st 2022
A recent study found that giving sinoatrial node radiation therapy during chemoradiotherapy may increase the likelihood of atrial fibrillation in patients with small cell lung cancer and non–small cell lung cancer.
Charles M. Rudin, MD, PhD, Examines Tiragolumab Plus Atezolizumab in Untreated Extensive-Stage Small Cell Lung CancerSeptember 9th 2022
Charles M. Rudin, MD, PhD, discussed results of the phase 3 SKYSCRAPER-02 trial examining atezolizumab with carboplatin and etoposide with or without tiragolumab in untreated extensive-stage small cell lung cancer.
Pembrolizumab and Etoposide Continue to Demonstrate Clinically Meaningful Survival Benefit in Untreated ES-SCLCAugust 9th 2022
After approximately 3.5 years of follow-up, patients with treatment-naive extensive-stage small cell lung cancer continued to derive survival benefit from pembrolizumab and etoposide.
Talazoparib Plus Low-Dose Temozolomide Bests Historical Controls in R/R ES-SCLCAugust 8th 2022
Data from the phase 2 UCLA/TRIO-US L-07 trial presented at 2022 WCLC revealed that efficacy with talazoparib plus temozolomide improves upon historical controls in patients with extensive-stage small cell lung cancer.
Preliminary Results Show Second-line Lurbinectedin Plus Pembrolizumab Safe, Effective in Relapsed SCLCJune 6th 2022
Preliminary findings of data from the phase 1/2 LUPER study demonstrate that treatment with lurbinectedin combined with pembrolizumab elicits promising efficacy in patients with metastatic small-cell lung cancer that has failed to respond to chemotherapy.
Adding Tiragolumab to Atezolizumab Plus Chemotherapy Does Not Improve Outcomes in Small Cell Lung CancerJune 5th 2022
The addition of tiragolumab to atezolizumab plus carboplatin and etoposide did not yield improved overall survival or progression-free survival rates in patients with extensive-stage small cell lung cancer.
Investigators Identify Markers Predictive of Durvalumab/Chemo Responses for ES-SCLCApril 11th 2022
Those with inflamed T cell or YAP1–positive extensive-stage small cell lung cancer were likely to gain an improvement in overall survival following treatment with durvalumab and chemotherapy vs those with other overexpressed biomarkers.
First-Line Tiragolumab Combo Misses PFS Co-Primary End Point in ES-SCLCApril 2nd 2022
Although tiragolumab plus atezolizumab and chemotherapy missed the primary end point of progression-free survival superiority in the phase 3 SKYSCRAPER-02 trial in patients with extensive-stage small cell lung cancer, it will continue to be evaluated in non–small cell lung cancer.
Phase 3 Study of First-Line Serplulimab/Chemotherapy Meets Primary End Point in ES-SCLCDecember 9th 2021
Treatment with serplulimab yielded a significant improvement in overall survival in combination with chemotherapy in patients with previously untreated extensive-stage small cell lung cancer.
WBRT Plus Radiation Boost Improves Survival Outcomes for Small Cell Lung Cancer With Brain MetastasesDecember 5th 2021
Compared with whole brain radiotherapy alone, the addition of local radiation boost to whole brain radiotherapy improved overall survival and progression-free survival among patients with small cell lung cancer and brain metastases.
Trilaciclib Prior to Chemotherapy Reduces Need for Supportive Care for Chemo-Induced Myelosuppression in ES-SCLCNovember 1st 2021
On or after week 5 of treatment with chemotherapy, trilaciclib reduced the need for supportive care therapies in patients with extensive-stage small-cell lung cancer.
Anlotinib Plus Irinotecan or Docetaxel Shows Promising Efficacy in SCLCOctober 11th 2021
Patients with small cell lung cancer who failed first-line treatment within 6 months were examined for efficacy of anlotinib plus chemotherapy in a phase 2 trial whose results were presented at the 2021 ESMO Congress.
Prophylactic Cranial Irradiation With Hippocampal Avoidance Preserves Cognitive Function During SCLC TreatmentAugust 22nd 2021
Hippocampal avoidance–prophylactic cranial irradiation was associated with better cognitive function preservation versus standard prophylactic cranial irradiation for small cell lung cancer.
Higher-Dose Radiotherapy Improved Survival, Maintained Level of Toxicity for Limited-Stage SCLCMarch 29th 2021
Data from The Lancet Oncology found that higher-dose radiotherapy of 60 Gy for patients with small cell lung cancer resulted in survival benefit while maintaining the toxicity profile compared with a radiotherapy at a dose of 45 Gy.
Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung CancerMarch 16th 2021
Original research published in the journal ONCOLOGY® explored the impacts of treatment refusal in patients with small cell lung cancer.
FDA Approves Trilaciclib for Patients With SCLC Being Treated With ChemoFebruary 12th 2021
The approval of trilaciclib was based on results from a pooled analysis of intent-to-treat datasets from 3 studies of patients with extensive-stage small cell lung cancer in which patients received standard chemotherapy plus either trilaciclib or placebo.
Specific Racial, Socioeconomic Factors Associated with Improved Survival Rates for Patients with LS-SCLCFebruary 5th 2021
Racial and socioeconomic factors were associated with varying levels of survival for patients with limited-stage small cell lung cancer, with improved survival noted among African American and Asian patients compared with White patients.